MV2 protocol

chemotherapy protocol consisting of mitoxantrone, etoposide, mitoguazone, and vinblastine; used in the treatment of malignant lymphoma and Hodgkin's disease

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MV2 protocol
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MV2 protocol
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MV2 protocol
Organic Chemicals: 133
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        MV2 protocol
  - Anthracenes: 12
    - Anthrones: 12
      - Anthraquinones: 788
        Mitoxantrone: 2907
        MV2 protocol
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - Etoposide: 10706
      - MV2 protocol
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vinblastine: 3373
        MV2 protocol
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vinblastine: 3373
        MV2 protocol
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vinblastine: 3373
        MV2 protocol